Alumis Inc. (NASDAQ:ALMS) Director Purchases $112,244.88 in Stock

Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director Alan Colowick purchased 16,104 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were acquired at an average price of $6.97 per share, with a total value of $112,244.88. Following the purchase, the director now owns 16,104 shares of the company's stock, valued at approximately $112,244.88. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Alumis Stock Down 26.5 %

NASDAQ:ALMS traded down $2.67 during mid-day trading on Tuesday, reaching $7.40. 882,835 shares of the company were exchanged, compared to its average volume of 315,163. Alumis Inc. has a 12 month low of $3.18 and a 12 month high of $13.53. The company has a fifty day moving average of $5.62 and a 200 day moving average of $8.15.

Analyst Ratings Changes

Several equities analysts recently commented on ALMS shares. HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Alumis in a research report on Wednesday, March 26th. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Finally, Oppenheimer initiated coverage on shares of Alumis in a research report on Thursday, January 30th. They set an "outperform" rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $26.00.

Hedge Funds Weigh In On Alumis

A number of large investors have recently modified their holdings of ALMS. Foresite Capital Management VI LLC bought a new position in Alumis in the 4th quarter worth approximately $33,033,000. Samsara BioCapital LLC bought a new stake in shares of Alumis during the third quarter worth $34,886,000. Geode Capital Management LLC acquired a new position in shares of Alumis during the third quarter valued at $3,266,000. Norges Bank acquired a new position in shares of Alumis during the fourth quarter valued at $1,606,000. Finally, Foresite Capital Management V LLC boosted its holdings in Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company's stock valued at $45,426,000 after acquiring an additional 194,459 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.